4 ms·

> in a modern environment that is hostile to it. Our ancient environment was hostile as well. > It patches malfunctioning reward centers It has an impact on

> in a modern environment that is hostile to it. Our ancient environment was hostile as well. > It patches malfunctioning reward centers It has an impact on them. It does not "patch" them. This is not a rational way to describe any drug. > it reduces overall inflammation It can inhibit certain inflammatory pathways. > it provide cardiovascular protective properties. It reduces the number of cardiovascular events. Whether that number is normal to begin with is not considered here. > We need more information and research. You certainly do.

toomuchtodo 2y ago
You're free to your opinion (legit, no snark intended), the market will deliver to the demand. The cost benefit ratio is obvious, even accounting for potential side effects at scale. https://www.axios.com/2024/01/18/ozempic-wegovy-weight-loss-drugs-states-map https://www.axios.com/2024/01/18/ozempic-wegovy-weight-loss-... https://www.axios.com/2024/01/19/weight-loss-drugs-america-obesity-diabetes-risks https://www.axios.com/2024/01/19/weight-loss-drugs-america-o... https://recursiveadaptation.com/p/the-growing-scientific-case-for-using https://recursiveadaptation.com/p/the-growing-scientific-cas... https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs https://www.jpmorgan.com/insights/global-research/current-ev... Edit: I simply do not understand the hostility towards this simple intervention, my apologies.
- akira2501 2y ago
  > You're free to your opinion Oh. Thank you. That's very generous. I assumed we started from that position but apparently not. > the market will deliver to the demand. Yes, because our healthcare market is perfect, and we should acquiesce to it's demands. The same could be said of opioid pain killers. > The cost benefit ratio is obvious Which entities cost benefit ratio, exactly? The patients? Are you _sure_ you have data which allows you to say that? > even accounting for potential side effects at scale. You're free to your opinion. The market will repeat history.
Teever 2y ago
You seem hostile to this possible solution. Can you explain why?

toomuchtodo 2y ago

You're free to your opinion (legit, no snark intended), the market will deliver to the demand. The cost benefit ratio is obvious, even accounting for potential side effects at scale. https://www.axios.com/2024/01/18/ozempic-wegovy-weight-loss-drugs-states-map https://www.axios.com/2024/01/18/ozempic-wegovy-weight-loss-... https://www.axios.com/2024/01/19/weight-loss-drugs-america-obesity-diabetes-risks https://www.axios.com/2024/01/19/weight-loss-drugs-america-o... https://recursiveadaptation.com/p/the-growing-scientific-case-for-using https://recursiveadaptation.com/p/the-growing-scientific-cas... https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs https://www.jpmorgan.com/insights/global-research/current-ev... Edit: I simply do not understand the hostility towards this simple intervention, my apologies.

akira2501 2y ago
> You're free to your opinion Oh. Thank you. That's very generous. I assumed we started from that position but apparently not. > the market will deliver to the demand. Yes, because our healthcare market is perfect, and we should acquiesce to it's demands. The same could be said of opioid pain killers. > The cost benefit ratio is obvious Which entities cost benefit ratio, exactly? The patients? Are you _sure_ you have data which allows you to say that? > even accounting for potential side effects at scale. You're free to your opinion. The market will repeat history.

Teever 2y ago

You seem hostile to this possible solution. Can you explain why?